METHOD FOR ASSESSING ANGIOGENIC POTENTIAL OF SCAFFOLDS Russian patent published in 2020 - IPC A61B10/00 G09B23/28 G01N33/68 G01N33/573 C07K14/705 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to experimental surgery, and can be used for assessment of scaffolds angiogenic potential. Scaffold is implanted in the form of a disc under the skin of rats, after which blood is sampled in amount of 3–5 ml under anaesthesia. Blood is centrifuged to produce serum in which the concentration of vascular endothelium growth factor A-VEGF is determined. Blood is sampled 7 days after implantation. Additionally, serum concentration of syndecan-1 is determined. Ratio of VEGF to syndecan-1 is calculated. For normalization of the ratio of concentrations of VEGF and syndecan-1, it is multiplied by a correction factor K, defined as the ratio of median values of syndecan-1 and VEGF concentrations in intact animals. If normalized value of ratio of concentrations of VEGF and syndecan-1 does not exceed 2, then matrices do not have angiogenic potential. If the ratio is more than 2, then the matrices have an angiogenic potential.

EFFECT: method provides more accurate assessment of the angiogenic potential of the biodegradable scaffold at the early stages of a subcutaneous implantation test by using a combination of angiogenesis induction marker concentration and endothelial glycocalyx stability, which makes it possible to characterize intensity and direction of structural remodeling microcirculatory channel.

1 cl, 3 tbl, 2 ex